glaxo shares higher forecasts , page-2

"Glaxo shares have gained 21 percent in the past year on demand for its Relenza flu treatment, the only other drug that's shown promise against bird flu. ``It's a multibillion-dollar market,'' said Bob Pooler, an analyst at Lombard Odier Darier Hentsch & Cie. in Zurich."

this is a paragraph from the link you posted. i don't understand how this impacts on a company the size of glaxo but the market does not seem to think it has much impact on a much smaller company in biota